Mitochondrial disease is a group of genetic disorders in which the mitochondria, the structures inside your cells that produce energy, don’t work properly. Because nearly every cell in your body depends on mitochondria for fuel, these diseases can affect almost any organ system, especially energy-hungry tissues like the brain, heart, muscles, and liver. Prevalence estimates suggest roughly 9 per 100,000 adults are affected, though many cases go undiagnosed for years.
How Mitochondria Power Your Cells
Mitochondria convert the food you eat into a molecule called ATP, which is essentially your body’s energy currency. Every time you think, move, or breathe, your cells spend ATP. Beyond energy production, mitochondria also help build amino acids, lipids, and other molecules your cells need to function and repair themselves.
In mitochondrial disease, genetic mutations disrupt the chain of chemical reactions that generates ATP. When this energy-production line slows down or stalls, two things happen: cells don’t get enough energy, and they accumulate harmful byproducts called free radicals. Those free radicals damage the mitochondria’s own DNA, which further reduces energy output and creates a worsening cycle of cellular stress. The result is organs that gradually lose function, particularly the ones that burn the most energy.
Why It Runs in Families Differently
Mitochondrial disease has unusual inheritance patterns because mitochondria carry their own small set of DNA, separate from the 23 pairs of chromosomes in the cell’s nucleus. Mitochondrial DNA is inherited exclusively from the mother. That means a father with a mitochondrial DNA mutation will not pass it to any of his children, while a mother with the same mutation will pass it to all of hers.
Not all mitochondrial diseases follow this maternal pattern, though. Many are caused by mutations in nuclear DNA, the standard chromosomes inherited from both parents. These follow the more familiar inheritance rules: autosomal dominant, autosomal recessive, or X-linked. Some mutations also arise spontaneously during embryonic development, with no family history at all. Large-scale deletions in mitochondrial DNA, for instance, typically arise de novo rather than being passed down.
One complicating factor is a concept called heteroplasmy. Each cell contains hundreds or thousands of mitochondria, and not all of them necessarily carry the same mutation. The ratio of healthy to mutated mitochondria can vary from cell to cell and from organ to organ, which is one reason two people with the same genetic mutation can have vastly different symptoms.
Symptoms Across the Body
Because mitochondria are everywhere, the symptoms of mitochondrial disease are remarkably diverse. The organs hit hardest tend to be those with the highest energy demands.
- Brain and nervous system: migraine headaches, seizures, trouble with balance and coordination, developmental delays in children, and progressive cognitive decline.
- Muscles: fatigue, weakness, and exercise intolerance are the hallmark symptoms of mitochondrial myopathy. Even mild physical activity can feel disproportionately exhausting.
- Heart: abnormal heart rhythms or heart block, which can range from unnoticeable to life-threatening.
- Liver: progressive liver disease is a feature of certain subtypes, including mitochondrial DNA depletion syndromes.
- Eyes and ears: vision loss, drooping eyelids, and hearing loss appear in several mitochondrial syndromes.
- Endocrine system: diabetes and short stature are common in some forms.
Many people experience symptoms in multiple organ systems simultaneously, which is often the first clue that something mitochondrial is going on. A child with seizures, muscle weakness, and hearing loss, for example, presents a pattern that points away from a single-organ diagnosis.
Well-Known Mitochondrial Syndromes
While dozens of specific conditions fall under the mitochondrial disease umbrella, a few named syndromes appear most frequently in clinical practice.
MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) typically emerges between ages 2 and 15, after a period of normal early development. Its defining feature is stroke-like episodes that cause sudden weakness on one side of the body or vision loss, but these strokes don’t follow the usual blood-vessel patterns seen on brain imaging. Children with MELAS may also develop seizures, recurring severe headaches, vomiting, muscle weakness, diabetes, and hearing loss. Some cases appear in infancy, and others don’t surface until age 40.
Leigh syndrome predominantly affects young children, causing progressive neurological decline, seizures, and vomiting. It tends to be more severe and earlier in onset than MELAS.
MERRF (myoclonus epilepsy with ragged red fibers) is characterized by a specific type of jerking seizure called myoclonus, along with muscle weakness and coordination problems. Genetic testing is needed to distinguish it definitively from MELAS, since the two share overlapping features.
Leber hereditary optic neuropathy (LHON) primarily causes rapid, painless vision loss, usually in young adults. It is one of the best-studied mitochondrial diseases and the furthest along in gene therapy research.
Kearns-Sayre syndrome is distinguished by progressive paralysis of the eye muscles, an unusual form of retinal degeneration, and heart conduction problems that typically appear before age 20.
How Mitochondrial Disease Is Diagnosed
Diagnosing mitochondrial disease is notoriously difficult because its symptoms mimic many other conditions. The process usually begins when a doctor notices unexplained problems in multiple organ systems that don’t fit neatly into a single diagnosis.
Genetic testing has become the primary diagnostic tool. Rather than testing one gene at a time, specialists now favor next-generation sequencing panels that cover all known mitochondrial disease genes at once. Single-gene testing is generally avoided because mutations in different genes can produce identical symptoms. If a gene panel comes back negative but suspicion remains high, whole-exome sequencing, which reads nearly all protein-coding genes, is the next step.
Muscle biopsy was long considered the gold standard, and it still plays a role when genetic testing is inconclusive. A small sample, usually taken from the thigh, can reveal characteristic structural abnormalities in the mitochondria and allow direct measurement of how well the energy-production chain is functioning. Muscle tissue can also detect mutations present at low levels or confined to specific tissues that blood-based genetic tests might miss. With the improving reach of molecular testing, however, biopsy is now reserved for cases where DNA results alone can’t confirm the diagnosis.
Managing the Disease Day to Day
There is currently no cure for mitochondrial disease. Treatment focuses on supporting energy production, reducing symptom burden, and preventing crises.
Most patients are prescribed a combination of supplements sometimes called a “mitochondrial cocktail.” Coenzyme Q10 (CoQ10) is the cornerstone. It plays a direct role in the mitochondrial energy chain and also acts as an antioxidant, helping to neutralize the excess free radicals that damaged mitochondria produce. L-carnitine helps shuttle fatty acids into mitochondria so they can be burned for fuel, and it clears out potentially toxic byproducts that accumulate when energy metabolism is impaired. Creatine serves as a backup energy source for muscles and is especially useful in patients with prominent muscle symptoms, though evidence supports its use more broadly.
These supplements don’t reverse the underlying genetic defect, but many patients report improvements in energy and exercise tolerance. The response varies considerably from person to person.
Avoiding Metabolic Crises
Children and adults with mitochondrial disease are vulnerable to rapid, dangerous deterioration when their bodies face physiological stress. Common triggers include infections, prolonged fasting, dehydration, and high fevers. During these episodes, the already compromised mitochondria simply can’t keep up with the body’s spiking energy demands, and multiple organ systems can decompensate quickly.
Certain medications also pose specific risks. Valproic acid, a widely used seizure medication, is particularly dangerous for patients with mutations in the POLG gene and those with mitochondrial liver disease. Patients and caregivers typically carry medical alert information listing medications to avoid and protocols for emergency care during illness.
Practical prevention centers on never skipping meals for extended periods, staying well hydrated during illness, treating fevers aggressively, and seeking medical attention early when infections develop rather than waiting them out.
Gene Therapy on the Horizon
The most advanced gene therapy efforts target LHON, the form of mitochondrial disease that causes vision loss. Multiple clinical trials have used a viral delivery system to insert a working copy of the faulty gene into the cell nucleus, where it produces the protein the mitochondria need. One therapy, lenadogene nolparvovec, has reached Phase 3 clinical trials. The approach, called allotopic expression, works around the challenge of delivering genes directly into mitochondria by instead placing a modified version in the nucleus with a targeting signal that routes the resulting protein to the right place.
More precise tools like base editors, which can correct individual DNA letters within mitochondria, remain in preclinical development. The unique biology of mitochondrial DNA, including the fact that each cell has thousands of copies, makes gene editing considerably more complex than for nuclear genes.